利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.014 秒)

    ANTI-CDH3 HUMANIZED ANTIBODY, DRUG CONJUGATE THEREOF, AND USE THEREOF
    1.
    发明申请
    ANTI-CDH3 HUMANIZED ANTIBODY, DRUG CONJUGATE THEREOF, AND USE THEREOF 有权
    抗CDH3人类抗体，与其结合的药物及其用途

    公开(公告)号：US20160152703A1

    公开(公告)日：2016-06-02

    申请号：US14768151

    申请日：2014-02-14

    申请人： PERSEUS PROTEOMICS INC.

    发明人： Keisuke ISHII ,  Katsuyuki MITOMO ,  Katsushi KOUDA ,  Fumiko NOMURA ,  Yoko KAYUKAWA ,  Tadashi MATSUURA

    IPC分类号： C07K16/28

    CPC分类号： C07K16/28 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6889 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

    摘要： It is an object of the present invention to produce an anti-CDH3 humanized antibody having lower immunogenicity, and to provide an anti-CDH3 humanized antibody drug conjugate comprising the aforementioned anti-CDH3 humanized antibody that more efficiently kills cancer cells expressing CDH3. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody which comprises complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No. NITE BP-1536, and complementarity determining region sequences derived from the light chain variable region thereof, and which also comprises a heavy chain human subgroup III consensus framework sequence or a human germline sequence that is selected under optimal alignment as a framework region sequence of the heavy chain variable region, and a light chain human κ subgroup I consensus framework sequence or a human germline sequence that is selected under optimal alignment as a framework region sequence of the light chain variable region.

    摘要翻译： 本发明的目的是制备具有较低免疫原性的抗CDH3人源化抗体，并提供包含上述抗CDH3人源化抗体的抗CDH3人源化抗体药物偶联物，其更有效地杀死表达CDH3的癌细胞。 本发明通过将具有细胞毒性的药物与抗CDH3人源化抗体缀合而提供抗CDH3人源化抗体和药物的缀合物，其包含衍生自具有加入细胞的细胞产生的抗体的重链可变区的互补决定区序列 NITE BP-1536，以及衍生自其轻链可变区的互补决定区序列，并且还包含在最佳比对下作为框架区序列选择的重链人亚组III共有框架序列或人种系序列 的重链可变区，以及轻链人和kgr; 亚组I共有框架序列或在最佳比对下选择的人种系序列作为轻链可变区的框架区序列。